OTCMKTS:BRTX BioRestorative Therapies (BRTX) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free BRTX Stock Alerts $1.27 -0.07 (-5.22%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$1.25▼$1.3650-Day Range$1.27▼$1.5052-Week Range$1.20▼$7.13Volume84,348 shsAverage Volume534,799 shsMarket Capitalization$8.60 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC Filings Get BioRestorative Therapies alerts: Email Address BioRestorative Therapies MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,081.1% Upside$15.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.17Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.52) to ($2.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.52 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBioRestorative Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBioRestorative Therapies has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for BRTX. Previous Next 0.0 Dividend Strength Dividend YieldBioRestorative Therapies does not currently pay a dividend.Dividend GrowthBioRestorative Therapies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BRTX. Previous Next 1.0 News and Social Media Coverage News SentimentBioRestorative Therapies has a news sentiment score of -0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for BioRestorative Therapies this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for BRTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added BioRestorative Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioRestorative Therapies insiders have not sold or bought any company stock.Percentage Held by Insiders21.60% of the stock of BioRestorative Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions69.38% of the stock of BioRestorative Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BioRestorative Therapies are expected to grow in the coming year, from ($3.52) to ($2.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioRestorative Therapies is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioRestorative Therapies is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioRestorative Therapies has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About BioRestorative Therapies Stock (OTCMKTS:BRTX)BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.Read More BRTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BRTX Stock News HeadlinesApril 23, 2024 | americanbankingnews.comBioRestorative Therapies (BRTX) vs. Its Peers Critical SurveyApril 20, 2024 | americanbankingnews.comContrasting BioRestorative Therapies (BRTX) & Its PeersApril 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 19, 2024 | americanbankingnews.comReviewing BioRestorative Therapies (BRTX) & The CompetitionApril 19, 2024 | markets.businessinsider.comOptimistic Outlook for BioRestorative Therapies Backed by Clinical and Strategic AdvancesApril 17, 2024 | msn.comBioRestorative Therapies (BRTX) Price Target Decreased by 16.00% to 10.71April 14, 2024 | finance.yahoo.com10 Micro-Cap Healthcare Stocks Insiders Are BuyingFebruary 16, 2024 | investing.comBioRestorative Therapies Inc (BRTX)April 25, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.February 14, 2024 | finanznachrichten.deBioRestorative Therapies, Inc.: BioRestorative Therapies Presents Promising Data at Orthopaedic Research Society 2024 Annual MeetingFebruary 6, 2024 | msn.comPRSO, AKRO and MIRA among pre-market losersDecember 20, 2023 | forbes.comGut Health Could Play A Role In How Blood Cancer Patients Respond To New TherapiesDecember 12, 2023 | marketwatch.comBioRestorative Therapies Shares Rise 14% on Allowance for Patent ApplicationDecember 12, 2023 | finance.yahoo.comBioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity ProgramNovember 9, 2023 | cnet.comBest Light Therapy Lamps for 2023October 9, 2023 | finance.yahoo.comBioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York CitySeptember 18, 2023 | seekingalpha.comBioRestorative Therapies' 10% shareholder Broadrick Dale increases holdingSeptember 18, 2023 | finance.yahoo.comRoth MKM Analyst Projects An Impressive Price Target of $15 Over The Next 12 Months For BioRestorative Therapies (NASDAQ: BRTX), Says “Low Valuation Undeserved”September 12, 2023 | finanznachrichten.deBioRestorative Therapies, Inc: BioRestorative Therapies Enters into Supply Agreement with Evolutionary BiologicsSeptember 12, 2023 | stockhouse.comBioRestorative Therapies Enters into Supply Agreement with Evolutionary BiologicsSeptember 8, 2023 | finance.yahoo.comBioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc DiseaseAugust 30, 2023 | msn.com$BRTX Is Looking To Treat Chronic Pain Without The Need For Class-A DrugsAugust 29, 2023 | benzinga.comAs America Grapples With A Deadly Opioid Epidemic, BioRestorative Therapies Is Looking To Treat Chronic Pain Without The Need For Class-A DrugsAugust 15, 2023 | msn.comRoth MKM Reiterates BioRestorative Therapies (BRTX) Buy RecommendationAugust 8, 2023 | finance.yahoo.comMirati (MRTX) Reports Q2 Loss, Misses Revenue EstimatesJuly 27, 2023 | msn.com$BRTX: Insights From A Specialist On Stem Cell-Based Therapies And The Need For Spinal Care ReformJuly 27, 2023 | finance.yahoo.comInsider Buying Alert: Lance Alstodt Acquires 4200 Shares of BioRestorative Therapies Inc (BRTX)See More Headlines Receive BRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/29/2024Today4/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:BRTX CUSIPN/A CIK1505497 Webwww.biorestorative.com Phone(631) 760-8100FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$15.00 Low Stock Price Target$15.00 Potential Upside/Downside+1,081.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,500,000.00 Net Margins-13,728.83% Pretax Margin-13,728.83% Return on Equity-120.47% Return on Assets-114.48% Debt Debt-to-Equity RatioN/A Current Ratio14.81 Quick Ratio14.81 Sales & Book Value Annual Sales$145,800.00 Price / Sales58.97 Cash FlowN/A Price / Cash FlowN/A Book Value$2.65 per share Price / Book0.48Miscellaneous Outstanding Shares6,770,000Free Float3,660,000Market Cap$8.60 million OptionableNot Optionable Beta61.51 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Lance Alstodt (Age 53)Chairman of the Board, President & CEO Comp: $400kMr. Robert Eugene Kristal (Age 56)Chief Financial Officer Comp: $175kMr. Francisco J. Silva (Age 49)Chief Scientist, VP of Research & Development, Secretary and Director Comp: $375kMr. Robert Paccasassi (Age 55)Vice President of Quality Assurance & Regulatory Compliance Comp: $233.95kDr. Wayne J. Olan M.D.Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory BoardKey CompetitorsPHAXIAM TherapeuticsNASDAQ:PHXMPulmatrixNASDAQ:PULMiBioNYSEAMERICAN:IBIOTherapix BiosciencesOTCMKTS:TRPXYCalidi BiotherapeuticsNYSEAMERICAN:CLDIView All CompetitorsInsidersDale BroadrickBought 1,000 shares on 7/27/2023Total: $2,800.00 ($2.80/share)Lance AlstodtBought 4,200 shares on 7/25/2023Total: $10,248.00 ($2.44/share)View All Insider Transactions BRTX Stock Analysis - Frequently Asked Questions Should I buy or sell BioRestorative Therapies stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioRestorative Therapies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BRTX shares. View BRTX analyst ratings or view top-rated stocks. What is BioRestorative Therapies' stock price target for 2024? 1 brokerages have issued 12-month target prices for BioRestorative Therapies' stock. Their BRTX share price targets range from $15.00 to $15.00. On average, they predict the company's share price to reach $15.00 in the next year. This suggests a possible upside of 1,081.1% from the stock's current price. View analysts price targets for BRTX or view top-rated stocks among Wall Street analysts. How have BRTX shares performed in 2024? BioRestorative Therapies' stock was trading at $1.7399 on January 1st, 2024. Since then, BRTX shares have decreased by 27.0% and is now trading at $1.27. View the best growth stocks for 2024 here. How were BioRestorative Therapies' earnings last quarter? BioRestorative Therapies, Inc. (OTCMKTS:BRTX) posted its quarterly earnings data on Friday, March, 29th. The company reported ($0.57) earnings per share (EPS) for the quarter. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.03 million. BioRestorative Therapies had a negative trailing twelve-month return on equity of 120.47% and a negative net margin of 13,728.83%. When did BioRestorative Therapies' stock split? Shares of BioRestorative Therapies reverse split on the morning of Wednesday, October 27th 2021. The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split. What other stocks do shareholders of BioRestorative Therapies own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioRestorative Therapies investors own include Co-Diagnostics (CODX), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), iBio (IBIO), Inovio Pharmaceuticals (INO), Vaxart (VXRT), Actinium Pharmaceuticals (ATNM), OPKO Health (OPK). How do I buy shares of BioRestorative Therapies? Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BRTX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThese AI trades triggered this morning (545% return)Prosper Trading AcademyPentagon contract could send this $2 AI stock soaringBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioRestorative Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
